FIGURE

Fig. 1.

ID

ZDB-FIG-210518-91

Publication

Oprişoreanu et al., 2021 - Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1.

Automated small-molecule compound screening follows a two-step workflow. (A) Schematic representation of the axonal phenotype in chodl−/−; mnx1:GFP embryos (left) with stalled axons at the horizontal myoseptum (HM), and zebrafish model of SMA (UBA1 model, right) showing abnormal motor axons, as used in drug screening. Chemical compounds that rescue the chodl−/−; mnx1:EGFP axonal phenotype are tested again using the UBA1 model. SC, spinal cord; NC, notochord. (B) Schematic representation of timeline and workflow of the experimental protocol. At 8 hpf, zebrafish eggs are arrayed in a 24-well plate (six eggs per well) and incubated in drug solution overnight. The next day (day 2) the 28-30 hpf embryos are moved from the 24-well plate into a 96-well plate (three embryos per well) followed by automated imaging using the VAST BioImager. In a single imaging session, between 16 and 20 chemical compounds can be tested with six embryos per compound.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Dis. Model. Mech.